William Levy, MD
Endocrinology, Diabetes & Metabolism · Waldorf, MDNPI 1801826342
Payments from drug & device makers
Across 193 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$667
- Novo Nordisk$655
- AbbVie$276
- Abbott$257
- Boehringer Ingelheim$236
- Sanofi-aventis U.S. LLC$233
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$2726%
- Food & beverage$4,10193%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 34 | $667 |
| Novo Nordisk | 32 | $655 |
| AbbVie | 12 | $276 |
| Abbott | 11 | $257 |
| Boehringer Ingelheim | 10 | $236 |
| Sanofi-aventis U.S. LLC | 12 | $233 |
| Dexcom, Inc. | 4 | $202 |
| Sanofi US Services Inc. | 1 | $200 |
| Corcept Therapeutics | 8 | $195 |
| Medtronic(2 entities) | 7 | $145 |
| Amgen(2 entities) | 4 | $132 |
| AstraZeneca(2 entities) | 7 | $132 |
| Tandem Diabetes Care, Inc. | 4 | $119 |
| Madrigal Pharmaceuticals | 3 | $92 |
| Cequr Corporation | 4 | $90 |
| Shire North American Group Inc | 5 | $85 |
| Insulet Corporation | 3 | $76 |
| Sanofi | 1 | $72 |
| BETA Bionics, Inc. | 3 | $56 |
| Merck | 4 | $55 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Sequel Med Tech, LLC | 2 | $46 |
| Lifescan, Inc. | 2 | $44 |
| Radius Health, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $32 |
| IBSA Pharma Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 1 | $28 |
| Mannkind Corporation | 2 | $23 |
| GSK | 1 | $22 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Bayer | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Intuity Medical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,405 in reported general payments places this provider in the 65th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 254 | $498,896 |
| JardianceEmpagliflozin | 217 | $261,432 |
| TrulicityDulaglutide | 88 | $139,266 |
| FarxigaDapagliflozin Propanediol | 97 | $99,418 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $62,566 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 107 | $58,184 |
| MounjaroTirzepatide | 40 | $57,677 |
| RybelsusSemaglutide | 44 | $55,728 |
| JanuviaSitagliptin Phosphate | 42 | $47,575 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $44,616 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $42,123 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $37,039 |
| Novolog FlexpenInsulin Aspart | 97 | $31,446 |
| Humalog Kwikpen U-100Insulin Lispro | 72 | $30,081 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $24,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $655 | $554,625298 claims |
| Boehringer IngelheimJardiance, Tradjenta | $236 | $275,943230 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $667 | $196,943128 claims |
| AstraZenecaFarxiga | $132 | $99,41897 claims |
| MerckJanuvia, Janumet | $55 | $72,47964 claims |
| AbbVieSynthroid | $276 | $19,736193 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $233 | $17,94019 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $19 | $4,625296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Waldorf
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Nicholas ArgentoLaurel$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.